[Sending recorded video] Cellca Cell Line Development Technical Update: 9 weeks until RCB

Using Cellca cell line development, over 120 projects have been successfully completed.

Zaltrius is a top provider of cell line development services. It offers cost-effective and highly reliable technology platforms. Cellca cell line development consistently delivers clones for stable research cells that have undergone sufficient characterization. From DNA to research cell banks (RCB) in just 14 weeks, it achieves a minimum monoclonal antibody titer of 5g/L with a scalable fed-batch process.

• others

Next-generation GMP cell banking

Thorough characterization and documentation of similar master cell banks (MCB) and working cell banks (WCB) are crucial elements that lead to risk reduction and ensure the safety and product quality of all biologically derived products. An experienced team is leveraging CRO expertise to expand services such as cell bank manufacturing. ▪ Manufacturing in a closed system ▪ Quality assurance ▪ Integration into cell line development and biosafety services ▪ For your applications: from mAbs to vaccines

• others

Integrated services with expertise and industry leadership.

【Top Service Provider】 The foundation for the approval of new biopharmaceuticals is built on a robust analytical data package that demonstrates the safety, purity, and efficacy of the product. BioOutsource's analytical testing package combines physicochemical and biological analytical methods, allowing for detailed characterization tailored to each client. 【Client Management Organization】 Projects are carried out by cross-departmental teams, and client managers provide support and advice with high transparency throughout the entire lifecycle of the client's project. 【Industry-Leading Integrated Services】 By supporting the development and characterization of biopharmaceuticals from preclinical development to commercialization, we provide services tailored to our clients' needs.

• others

Conducted safety and characterization analysis tests on over 200 Chinese hamster ovary (CHO) cell bank samples.

CHO cells are the most widely used production cell lines in the pharmaceutical industry, and their safety profile has been established for over 20 years. Guidelines for the safety and characterization analysis of CHO production cell lines are harmonized with the International Conference on Harmonisation (ICH) Q5 (R1) "Virus Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin" and ICH Q5D "Derivation, Characterization, and Production of Cell Lines for the Manufacture of Biological Products (Biotechnology-derived Products | Biologically-derived Products)." Since 2007, Sartorius has conducted safety and characterization testing for over 200 Chinese Hamster Ovary (CHO) cell bank samples. Our researchers possess extensive knowledge and experience and will provide advice on optimal and cost-effective testing strategies that comply with chemical and regulatory requirements. We will also consider the history of the cell lines and raw materials used during bank manufacturing when proposing test packages.

• others

Introducing comprehensive solutions for safety testing of biological products and viral vaccines.

All biological products must undergo rigorous safety testing at both the development and manufacturing stages to confirm the characteristics of the product and host cells, as well as to ensure non-contamination. ▪ Exceptional technical expertise ▪ Rapid result delivery ▪ Extensive regulatory knowledge ▪ Enhanced quality assurance

• others

Comprehensively supporting the early development of biopharmaceuticals on an independent platform.

Physical and Chemical, as well as Biological Equivalence of Biosimilars | Similarity Assessment 【Expertise】 Industry-leading experience with over 12 biosimilar molecules and more than 30 biosimilar development companies 【Speed to Market】 Cost-effective results guaranteed through a comprehensive lineup of ready-made assays for the characterization and equivalence | similarity assessment of biosimilars 【Higher Quality Assurance】 Providing the necessary data for submission at the time of application, backed by exceptional regulatory and industry insights

• others

Advantech Toyo will be exhibiting at the trade show "JASIS 2026," which will be held at Makuhari Messe International Exhibition Hall. At this exhibition, manufacturers of analytical and scientific instruments will gather to showcase cutting-edge scientific and analytical systems and solutions. At our booth, we will display filter products for microbiological testing and environmental analysis, water quality testing products, pure and ultra-pure water production equipment, and culture-related equipment. Additionally, we will also showcase analytical balances from Mettler Toledo, along with equipment from other well-regarded manufacturers in the industry. Our sales and technical staff will be available to assist with product selection, so please feel free to stop by!

[Speakers] Nomura Research Institute, Ltd. Global Manufacturing Consulting Department Group Manager Hirokazu Shimo Senior Consultant Shoki Tokugawa Senior Consultant Wataru Hashimoto Consultant Masaaki Amano Consultant Tomoya Nakamura [Presentation Items] 1. Key Development Themes of Major OEMs 2. Development Approaches of Each OEM 2-1. Toyota 2-2. Tesla 2-3. Suzuki 2-4. Nissan 2-5. Honda 3. Development Approaches of Suppliers 4. Key Points for Strengthening Development Capabilities 5. Q&A / Business Card Exchange

[Speaker] Ayaka Motomura, Consultant, Business Transformation Unit, NTT Data Management Research Institute [Key Lecture Content] With the advancement of Physical AI, telecommunications carriers have the opportunity to evolve from being "companies that provide lines" to companies that connect and control AI and the physical world in real-time. This seminar will organize the changes in communication demand brought about by Physical AI and the business opportunities for telecommunications carriers, while explaining the role of AIOps as the first step towards entry. Furthermore, it will discuss strategies for monetizing in the Physical AI market by deploying the operational intelligence accumulated through AIOps to network APIs and industry-specific services, as well as the layers that telecommunications carriers should hold. [Lecture Topics] Chapter 1: The Competitive Structure of the "Real World" Rewritten by Physical AI Chapter 2: Reasons Why Opportunities for "Reversal" Arise for Telecommunications Carriers in the Era of Physical AI Chapter 3: The First Step Towards Physical AI Chapter 4: Shifting AIOps from "Defense" to "Offense" Chapter 5: The Layers to Hold in the Era of Physical AI [Q&A / Business Card Exchange]

[Instructor] Partner Ryoji Mori, Eichi Law Office [Key Lecture Content] This lecture will explain the revised Personal Information Protection Act of 2028. The three-year review this time is a major revision, and it is essential to first understand where and how the revisions have been made, as well as the overall picture of the amendments. Next, we will explain the individual amendments that are practically important. The key points are as follows, but it is important to note that both the strengthening and relaxation of obligations are occurring simultaneously, increasing overall complexity. At the time of the lecture, it is expected that subordinate laws and guidelines will not yet be published, but we will discuss points that require attention upon publication. We will distinguish between what is necessary across businesses and what varies by industry. [Lecture Items] 1. Expansion of consent exceptions: Relaxation of the difficulty of obtaining consent and expansion of academic research institutions 2. Statistical exceptions: System content and how to read complex provisions (plus learning about acceptability from controversies) 3. Strengthening regulations on biometric information and children's information: Caution required for age verification 4. Contactable personal-related information: Changes in external transmission responses 5. Review of outsourcing regulations: Addition and removal of obligations for contractors 6. Administrative fines: Narrow target range and low amounts (not worth fearing) 7. Q&A / Business card exchange

[Instructor] Innovation Analyst Andy Kondo [Key Lecture Content] *The latest content will be added (changed) as appropriate based on the on-site survey of IAA Transportation 2026.* From September 15 to 20, 2026, the largest commercial vehicle exhibition in Europe, IAA Transportation, will be held in Hanover, Germany. It is a gathering place for manufacturers of commercial vehicles such as trucks and buses, as well as the parts, energy, and software that support them, occurring every two years. The cost structure of logistics, urban transportation and the environment, energy transition, decarbonization efforts, and a microcosm of the industry will reveal the future business environment just a step ahead. In this seminar, an innovation analyst who has been observing major global exhibitions such as CES and Hannover Messe for many years will report shortly after the event based on on-site coverage. Has autonomous driving become the main focus in commercial vehicles? Where is the energy transition for large vehicles settling in terms of batteries, hydrogen, and alternative fuels? How far have Chinese companies come? Based on photos taken at the venue and observations of actual products, the seminar will delve into the implications for Japanese companies.